Royalty Pharma: SCH sells 100K Class A shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc (RPRX) reported that SCH Investment Partners LLC sold 100,000 Class A ordinary shares on November 17, 2026, at a weighted average price of $68.1471 per share; individual sale prices ranged from $67.78 to $68.58. The sale was made under a Rule 10b5-1 plan adopted by reporting person Christopher Hite, EVP & Chairman, Partnering, on March 20, 2026. After the sale, the LLC held 177,523 shares indirectly; Hite also held 23,200 shares directly.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Ordinary Shares F1, F2 | 100,000 | $68.1471 | $6.81M |
| Holding | Class A Ordinary Shares | -- | -- | -- |
Footnotes (2)
- F1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.78 to $68.58 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Key Terms
Rule 10b5-1 plan regulatory
weighted average price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.